Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
United States
USC Norris Comprehensive Cancer Center, Los Angeles, California Hoag Memorial Hospital Presbyterian, Newport Beach, California UCLA Hematology/Oncology - Santa Monica, Santa Monica, California Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, Colorado AdventHealth Cancer Institute, Celebration, Florida